Docstoc

2013 | Aarkstore.in || Primitive Neuroectodermal Tumor (PNET) – Pipeline Review, H2 2012

Document Sample
2013 | Aarkstore.in || Primitive Neuroectodermal Tumor (PNET) – Pipeline Review, H2 2012 Powered By Docstoc
					You can also request for sample page of above
mention reports on Customersupport@aarkstore.com
Price :
$ 2000 - PDF | $ 4000 - Site Licence | $ 6000 - Corporate Licence


Pages : 90
Summary


Global Markets Direct’s, Primitive Neuroectodermal Tumor (PNET) - Pipeline
Review, H2 2012, provides an overview of the indication’s therapeutic pipeline.
This report provides information on the therapeutic development for Primitive
Neuroectodermal Tumor (PNET), complete with latest updates, and special
features on late-stage and discontinued projects. It also reviews key players
involved in the therapeutic development for Primitive Neuroectodermal Tumor
(PNET). Primitive Neuroectodermal Tumor (PNET) - Pipeline Review, Half Year
is built using data and information sourced from Global Markets Direct’s
proprietary databases, Company/University websites, SEC filings, investor
presentations and featured press releases from company/university sites and
industry-specific third party sources, put together by Global Markets Direct’s
team.

Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.
Scope

- A snapshot of the global therapeutic scenario for Primitive Neuroectodermal
Tumor (PNET).
 - A review of the Primitive Neuroectodermal Tumor (PNET) products under
development by companies and universities/research institutes based on
information derived from company and industry-specific sources.
 - Coverage of products based on various stages of development ranging from
discovery till registration stages.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under
development for Primitive Neuroectodermal Tumor (PNET).
- Identify emerging players with potentially strong product portfolio and design
effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most
promising pipeline.
Table Of Contents

List of Tables 4
 List of Figures 4
 Introduction 5
 Global Markets Direct Report Coverage 5
 Primitive Neuroectodermal Tumor (PNET) Overview 6
 Therapeutics Development 7
 An Overview of Pipeline Products for Primitive Neuroectodermal Tumor
(PNET) 7
 Primitive Neuroectodermal Tumor (PNET) Therapeutics under Development
by Companies 9
 Primitive Neuroectodermal Tumor (PNET) Therapeutics under Investigation
by Universities/Institutes 10
 Late Stage Products 11
 Comparative Analysis 11
 Mid Clinical Stage Products 12
 Comparative Analysis 12
 Early Clinical Stage Products 13
 Comparative Analysis 13
 Primitive Neuroectodermal Tumor (PNET) Therapeutics – Products under
Development by Companies 14……………………..
More Related Reports:

http://www.aarkstore.com/publishers/pubreports.asp?PubId=4
9&pagenum=1

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) – Pipeline
Review, H2 2012

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline Review, H2
2012

Diabetic Peripheral Neuropathy – Pipeline Review, H2 2012

Opioid-Induced Constipation (OIC) – Pipeline Review, H2 2012

Premature Labor (Tocolysis) – Pipeline Review, H2 2012
For More details about above & other Reports
plz contact :


Lavanya
Aarkstore.com


Contact: Marketing team
Mob.No.918149852585
Email: enquiry@aarkstore.com
URL: http://www.aarkstore.com
http://in.linkedin.com/in/aarkstore
http://www.facebook.com/aarkstore

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:3
posted:1/4/2013
language:
pages:7